The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3 - PubMed (original) (raw)
. 2006 Jul 14;281(28):19310-9.
doi: 10.1074/jbc.M603225200. Epub 2006 May 11.
Affiliations
- PMID: 16690615
- DOI: 10.1074/jbc.M603225200
Free article
The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3
Melanie Funes et al. J Biol Chem. 2006.
Free article
Abstract
Mucins provide a protective barrier for epithelial surfaces, and their overexpression in tumors has been implicated in malignancy. We have previously demonstrated that Muc4, a transmembrane mucin that promotes tumor growth and metastasis, physically interacts with the ErbB2 receptor tyrosine kinase and augments receptor tyrosine phosphorylation in response to the neuregulin-1beta (NRG1beta) growth factor. In the present study we demonstrate that Muc4 expression in A375 human melanoma cells, as well as MCF7 and T47D human breast cancer cells, enhances NRG1beta signaling through the phosphatidylinositol 3-kinase pathway. In examining the mechanism underlying Muc4-potentiated ErbB2 signaling, we found that Muc4 expression markedly augments NRG1beta binding to A375 cells without altering the total quantity of receptors expressed by the cells. Cell-surface protein biotinylation experiments and immunofluorescence studies suggest that Muc4 induces the relocalization of the ErbB2 and ErbB3 receptors from intracellular compartments to the plasma membrane. Moreover, Muc4 interferes with the accumulation of surface receptors within internal compartments following NRG1beta treatment by suppressing the efficiency of receptor internalization. These observations suggest that transmembrane mucins can modulate receptor tyrosine kinase signaling by influencing receptor localization and trafficking and contribute to our understanding of the mechanisms by which mucins contribute to tumor growth and progression.
Similar articles
- Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways.
Jepson S, Komatsu M, Haq B, Arango ME, Huang D, Carraway CA, Carraway KL. Jepson S, et al. Oncogene. 2002 Oct 24;21(49):7524-32. doi: 10.1038/sj.onc.1205970. Oncogene. 2002. PMID: 12386815 - Muc4 is required for activation of ErbB2 in signet ring carcinoma cell lines.
Yokoyama A, Shi BH, Kawai T, Konishi H, Andoh R, Tachikawa H, Ihara S, Fukui Y. Yokoyama A, et al. Biochem Biophys Res Commun. 2007 Mar 30;355(1):200-3. doi: 10.1016/j.bbrc.2007.01.133. Epub 2007 Feb 2. Biochem Biophys Res Commun. 2007. PMID: 17292332 - Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance.
Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL. Price-Schiavi SA, et al. Int J Cancer. 2002 Jun 20;99(6):783-91. doi: 10.1002/ijc.10410. Int J Cancer. 2002. PMID: 12115478 - Cell signaling through membrane mucins.
Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA. Carraway KL, et al. Bioessays. 2003 Jan;25(1):66-71. doi: 10.1002/bies.10201. Bioessays. 2003. PMID: 12508284 Review. - Muc4/sialomucin complex in the mammary gland and breast cancer.
Carraway KL, Price-Schiavi SA, Komatsu M, Jepson S, Perez A, Carraway CA. Carraway KL, et al. J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):323-37. doi: 10.1023/a:1011327708973. J Mammary Gland Biol Neoplasia. 2001. PMID: 11547901 Review.
Cited by
- Cancer immune exclusion: breaking the barricade for a successful immunotherapy.
Bruni S, Mercogliano MF, Mauro FL, Cordo Russo RI, Schillaci R. Bruni S, et al. Front Oncol. 2023 May 22;13:1135456. doi: 10.3389/fonc.2023.1135456. eCollection 2023. Front Oncol. 2023. PMID: 37284199 Free PMC article. Review. - Multi-omics analysis of the Indian ovarian cancer cohort revealed histotype-specific mutation and gene expression patterns.
Mhatre A, Koroth J, Manjunath M, Kumar S S, Gawari R, Choudhary B. Mhatre A, et al. Front Genet. 2023 Apr 6;14:1102114. doi: 10.3389/fgene.2023.1102114. eCollection 2023. Front Genet. 2023. PMID: 37091785 Free PMC article. - The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis.
Stoup N, Liberelle M, Schulz C, Cavdarli S, Vasseur R, Magnez R, Lahdaoui F, Skrypek N, Peretti F, Frénois F, Thuru X, Melnyk P, Renault N, Jonckheere N, Lebègue N, Van Seuningen I. Stoup N, et al. Cancers (Basel). 2021 Nov 16;13(22):5746. doi: 10.3390/cancers13225746. Cancers (Basel). 2021. PMID: 34830899 Free PMC article. - The role of membrane mucin MUC4 in breast cancer metastasis.
Dreyer CA, VanderVorst K, Free S, Rowson-Hodel A, Carraway KL. Dreyer CA, et al. Endocr Relat Cancer. 2021 Nov 24;29(1):R17-R32. doi: 10.1530/ERC-21-0083. Endocr Relat Cancer. 2021. PMID: 34726614 Free PMC article. Review. - MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
Sagar S, Leiphrakpam PD, Thomas D, McAndrews KL, Caffrey TC, Swanson BJ, Clausen H, Wandall HH, Hollingsworth MA, Radhakrishnan P. Sagar S, et al. Cancer Lett. 2021 Apr 10;503:91-102. doi: 10.1016/j.canlet.2021.01.015. Epub 2021 Jan 22. Cancer Lett. 2021. PMID: 33485947 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous